Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Allison Piluso
Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, KIR Genotyping, and Other Clinical Variables
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Related publications
Selecting the Best Haploidentical Donor
Seminars in Hematology
Hematology
“No Donor”? Consider a Haploidentical Transplant
Blood Reviews
Oncology
Hematology
The Impact of Donor KIR and Patient HLA-C Genotypes on Outcome Following HLA-identical Sibling Hematopoietic Stem Cell Transplantation for Myeloid Leukemia
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome After T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation With Posttransplant Cyclophosphamide
Journal of Immunology
Allergy
Immunology
Survival After T-Cell Replete Haploidentical Related Donor Hematopoietic Cell Transplantation (Haplo-Hct) Using Post-Transplant Cyclophosphamide (PT-CY) Compared With HLA-Matched Related Donor (MRD) Transplant for Lymphomas
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
The Impact of Graft Composition on Clinical Outcomes in Unmanipulated HLA-mismatched/haploidentical Hematopoietic SCT
Bone Marrow Transplantation
Transplantation
Hematology
Who Is the Best Haploidentical Donor for Acquired Severe Aplastic Anemia? Experience From a Multicenter Study
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Combination Treatment of Rituximab and Donor Platelets Infusion to Reduce Donor-Specific Anti-Hla Antibodies for Stem Cells Engraftment in Haploidentical Transplantation
Journal of Clinical Laboratory Analysis
Allergy
Immunology
Biochemistry
Public Health
Medical Laboratory Technology
Clinical Biochemistry
Hematology
Microbiology
Environmental
Occupational Health
Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect Against Relapse After Myeloablative, HLA Matched Hematopoietic Cell Transplantation
PLoS ONE
Multidisciplinary
